Table 2.
Association of age with molecular genetic alterations
| Total (n = 179) | Younger patients (n = 111) | Older patients (n = 68) | p value | |
|---|---|---|---|---|
| Mutation number (mean) | 2.08 | 1.83 | 2.50 | 0.003 |
| CEBPA | 32 (17.9) | 22 (19.8) | 10 (14.7) | 0.428 |
| TET2 | 30 (16.8) | 15 (13.5) | 15 (22.1) | 0.153 |
| ASXL1 | 25 (14.0) | 10 (9.0) | 15 (22.1) | 0.025 |
| NRAS | 21 (11.7) | 17 (15.3) | 4 (5.9) | 0.092 |
| NPM1 | 20 (11.2) | 12 (10.8) | 8 (11.8) | 1 |
| IDH2 | 18 (10.1) | 10 (9.0) | 8 (11.8) | 0.768 |
| FLT3–ITD | 18 (10.1) | 12 (10.8) | 6 (8.8) | 0.800 |
| DNMT3A | 16 (8.9) | 6 (5.4) | 10 (14.7) | 0.056 |
| KIT | 14 (7.8) | 12 (10.8) | 2 (2.9) | 0.083 |
| TP53 | 13 (7.3) | 4 (3.6) | 9 (13.2) | 0.034 |
| RUNX1 | 13 (7.3) | 5 (4.5) | 8 (11.8) | 0.081 |
| IDH1 | 12 (6.7) | 5 (4.5) | 7 (10.3) | 0.216 |
| WT1 | 9 (5.0) | 7 (6.3) | 2 (2.9) | 0.486 |
| GATA2 | 5 (2.8) | 2 (1.8) | 3 (4.4) | 0.370 |
| FLT3–TKD | 5 (2.8) | 3 (2.7) | 2 (2.9) | 1 |
| KRAS | 4 (2.2) | 3 (2.7) | 1 (1.5) | 1 |
| DNA methylation | 63 (35.2) | 30 (27.0) | 33 (48.5) | 0.004 |
| RNA splicing | 37 (20.7) | 16 (14.4) | 21 (30.9) | 0.013 |
| Chromatin architecture | 32 (17.9) | 12 (10.8) | 20 (29.4) | 0.002 |
| Transcriptional deregulation | 50 (27.9) | 31 (27.9) | 19 (27.9) | 1 |
| Activated signaling | 55 (30.7) | 42 (37.8) | 13 (19.1) | 0.012 |